Incubate Coalition

Making Medicine

Health EN ↓ 104 episodes

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of...

Be sure to visit the podcast's website and support the creator: www.spreaker.com

Author

Incubate Coalition

Category

Health

Podcast website

www.spreaker.com

Latest episode

Nov 19, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Dr. Ned Sharpless on China, FDA Reform & the Future of American Biotech 19.11.2026

Is America losing its competitive edge in biotechnology? And could new restrictions on U.S. investment in China ultimately hurt American patients and drug development? Former FDA Acting Commissioner and National Cancer Institute Director Dr. Ned Sharpless returns to the Making Medicine Podcast for a wide-ranging conversation with host John Stanford about China's growing biotech capabilities, Ameri...

RE-AIR: Myths vs. Facts: China, Biotech, and National Security 12.11.2026

Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech industry? We're revisiting this episode of Making Medicine, where host John Stanford examines five common claims shaping the debate over China, pharmaceutical innovation, national security, and American competitiveness.  As Washington continues...

The Faster Clinical Trials Act, MFN Fallout in Europe, and October’s Biotech Numbers 05.11.2026

What’s moving in biotech policy right now? In this Headlines episode of Making Medicine, host John Stanford runs through the month’s top stories shaping how medicines are discovered, developed, and delivered in America. Leading the headlines is the Faster Clinical Trials Act, a new bipartisan proposal to modernize clinical trials, reduce regulatory delays, and speed up drug development. From there...

Inside the COINS Act: How Treasury’s China Rule Could Reshape Drug Development 29.10.2026

Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines? The proposed regulations would restrict a broad range of transactions with Chinese companies. That could change how U.S. biotech companies partner, invest, and bring new therapies to American patients. But how far does the rule actually reach? In this Making Medicine Press Pass episode, ho...

Myths vs. Facts: China, Biotech, and National Security 22.10.2026

Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech industry? As Washington debates biotechnology investment restrictions and national security, Making Medicine host John Stanford examines five common claims shaping the conversation about China, pharmaceutical innovation, and American competitive...

Biotech Boom, Drug Lag: Japan's Innovation Paradox 15.10.2026

Japan has many of the ingredients of a world-class biotechnology ecosystem: leading scientific research, Nobel Prize-winning discoveries, and growing investment. Yet many innovative medicines reach Japanese patients later than in other markets, and some never launch at all. So what explains the gap? In this special Tokyo episode of the Making Medicine Podcast, host John Stanford is joined by Micha...

Ohio’s Biotech Boom: Gene Therapy, Investment & the Race with China 08.10.2026

Ohio is emerging as a major U.S. life sciences hub, with growing investment in biotech, gene therapy, biomanufacturing and pharmaceutical innovation. But what does it take to build a competitive biotech ecosystem outside traditional hubs like Boston and San Francisco? In this episode of the Making Medicine Podcast, host John Stanford sits down with Eddie Pauline, President & CEO of Ohio Life S...

AI in Drug Discovery: What Works, What’s Hype & What Comes Next 01.10.2026

Artificial intelligence could transform drug discovery and biotech, but not necessarily in the ways the biggest AI predictions suggest. Where can AI actually make drug development faster and more efficient, and where does the hype collide with the realities of biology? In this episode of the Making Medicine Podcast, host John Stanford sits down with Dr. Thomas Kaiser, co-founder and Chief Scientif...

China’s Biotech Rise: Clinical Trials, Drug Development & U.S. Competition 24.09.2026

China’s biotech industry is expanding rapidly, reshaping clinical trials, drug development, licensing and the global competition for biomedical innovation. What can the United States learn from what’s happening in China? In this episode of the Making Medicine Podcast, host John Stanford sits down with Tim Scott, President & CEO of Biocom, following a biotech delegation trip to Shanghai. Tim sh...

Biotech’s Biggest Stories: Drug Pricing, Access & R&D 17.09.2026

From billion-dollar drug development bets and looming patent cliffs to drug pricing, patient access and the future of U.S. clinical trials, some of the biggest stories in biotech are connected by one question: what will they mean for the medicines patients ultimately receive? In this episode of the Making Medicine Podcast, host John Stanford breaks down the stories he’s reading and watching across...

9 Years vs. 13: The Problem With the Pill Penalty 10.09.2026

Why does a small molecule medicine get nine years on the market before Medicare negotiation while a biologic gets 13? And what does that four-year difference mean for the medicines that do get developed? For 9/13 Day, the Making Medicine Podcast is revisiting some of our most important conversations about the pill penalty and its impact on biotech investment, drug development and patients. Under t...

Beyond the Sticker Price: The Real Economics of a $480,000 Cancer Drug 03.09.2026

A new pancreatic cancer medicine could double survival time. Its annual list price? $480,000. That number is getting lots of attention, but the economics of bringing breakthrough medicines to patients are more complex than a single price tag can convey. After more than a decade of development and billions of dollars invested, Revolution Medicines has brought a new treatment to patients with metast...

Can AI Reinvent How America Makes Medicine? | How America Makes Medicine Ep. 6 27.08.2026

🇺🇸 Artificial intelligence is reshaping biotech, drug discovery and medicine. But how much of the AI revolution is real, how much is hype, and what could it mean for the future of American medicine? In Part 6 of our How America Makes Medicine series, host John Stanford sits down with physician-scientist and venture capitalist Patrick Malone to explore how AI and machine learning could transform dr...

How Venture Capital Backed America's Biotech Engine | How America Makes Medicine Ep. 5 20.08.2026

🇺🇸 Venture capital helped build America's biotech industry, but what happens when that capital stops flowing? In Episode 5 of the How America Makes Medicine series, John Stanford sits down with Michael Rome, Managing Director and Head of Therapeutics Investing at Foresite Capital, to explore the role of biotech venture capital in building America's drug development ecosystem. The episode examines...

Betting on Biotech: Dr. Jeremy Levin's Playbook | How America Makes Medicine Ep. 4 13.08.2026

🇺🇸 Why does so much pharmaceutical innovation come from small biotech companies? And how do different parts of America's medicine ecosystem work together to turn scientific discoveries into medicines for patients? In this episode of How America Makes Medicine, John Stanford sits down with Dr. Jeremy Levin, a longtime pharmaceutical and biotechnology leader, to explore the interconnected ecosystem...

The Relay Continues: Building Biotechs That Save Lives | How America Makes Medicine Ep. 3 06.08.2026

🇺🇸 Every breakthrough medicine begins with a scientific discovery. But turning that discovery into a *treatment* that reaches patients*requires navigating one of the most challenging journeys in medicine. Before a new therapy can change lives, promising science must attract funding, become a startup company, navigate years of development, survive the *"Valley of Death,"* scale manufacturing, and u...

How Research Universities Power America’s Innovation Engine | How America Makes Medicine Ep. 2 30.07.2026

🇺🇸 Every breakthrough medicine starts somewhere. Discover how research universities, NIH funding, and American innovation change lives. Every new medicine’s journey begins long before it reaches a patient. In Episode 2 of our How America Makes Medicine series, John Stanford sits down with Kate Hudson of the Association of American Universities (AAU) to explain why research universities are one of...

250 Years of American Pharmaceutical Innovation | How America Makes Medicine Ep. 1 23.07.2026

🇺🇸 How America Makes Medicine begins with the remarkable story of 250 years of American pharmaceutical innovation. Welcome to How America Makes Medicine, a new seven-part series from the Making Medicine Podcast celebrating 250 years of American pharmaceutical innovation.  As the United States celebrates its *250th anniversary, this inaugural episode of the series traces the extraordinary journey f...

FDA Leadership, China & The Future of American Biotech 16.07.2026

🇺🇸 FDA leadership, China's growing role in clinical trials, NIH research, and biotechnology innovation are shaping the future of American medicine. This week on the Making Medicine Podcast, John Stanford breaks down the latest developments in the search for the next FDA Commissioner, including the three reported finalists: Dr. Heidi Overton, White House health policy adviser; Dr. Jeffrey Vacirca,...

Japan's Biotech Transformation: Drug Pricing, Clinical Trials & Global Investment 09.07.2026

Japan's biotech industry is at a crossroads. Drug pricing reform, clinical trials, venture capital investment, and life sciences policy are all in flux as the country tries to figure out its path forward.  This week on the Making Medicine Podcast, guest host John Guy, Incubate's Policy Director, is joined by John Gutierrez of Ascenta Capital and Josh Lipscomb, Incubate’s International Programs Man...

Maria Thacker Goethe on Biotech Growth, Clinical Trials & US Competitiveness 02.07.2026

Georgia's life sciences industry is growing fast. Biotech manufacturing, clinical trials, workforce development, and healthcare policy are reshaping America's innovation economy. This week on the Making Medicine Podcast, John Stanford sits down with Maria Thacker Goethe, President and CEO of Georgia Life Sciences, to discuss why Georgia has become one of the fastest-growing biotechnology hubs in t...

Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying 25.06.2026

FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad. In case you missed it: We are bringing one of our most critical recent conversations to unpack how regulatory uncertainty is shifting the future of medicine. FDA instability is reshaping biotech investment decisions in real time. Across the board...

China’s Biotech Rise: What Tim Scott Saw Inside Shanghai 18.06.2026

China's biotech innovation is accelerating. Clinical trials, NIH funding, and global competition are reshaping healthcare. Biocom’s President & CEO Tim Scott explains why America should focus on "playing to win" rather than "playing not to lose." China’s biotech industry is moving faster than many policymakers realize. From investigator-initiated clinical trials and massive patient registries...

Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery 11.06.2026

Rare diseases. Patient advocacy. Drug development. FDA partnerships. Clinical trials. Patient organizations have evolved into powerful engines of drug development, building registries, funding research, shaping clinical trial design, and partnering with regulators to accelerate new treatments. This week on the Making Medicine Podcast, John Stanford sits down with Lisa Bonebrake, Executive Director...

Healthcare Costs, PBMs & Why Manufacturers Oppose Drug Price Controls 04.06.2026

Healthcare costs. PBM reform. Drug price controls. FDA stability. American manufacturing. This week on the Making Medicine Podcast, John Stanford sits down with Charles Crain, Vice President of Domestic Policy at the National Association of Manufacturers, to discuss a new report examining the rising cost of healthcare and its impact on American manufacturers. Manufacturers provide health coverage...

Listen to the Making Medicine podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.